Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147837 | 0.93 | KMT2A (0.40) | KMT2AMEN1MAPTTHRATHRB | |
| SCHEMBL27932596 | 0.82 | TSHR (0.52) | KMT2AMEN1EPHX2 | |
| SCHEMBL260594 | 0.80 | THRA (0.36) | KMT2AMEN1THRATHRBEPHX2 | |
| SCHEMBL1314528 | 0.79 | MEN1 (0.56) | KMT2AMEN1 | |
| SCHEMBL637535 | 0.77 | TBXAS1 (0.35) | KMT2AMEN1THRATHRBEPHX2 | |
| SCHEMBL27793019 | 0.77 | CTSD (0.43) | KMT2AMEN1THRATHRBPHF8 | |
| SCHEMBL4928619 | 0.76 | LMNA (0.46) | KMT2AMEN1 | |
| SCHEMBL4937002 | 0.76 | MEN1 (0.39) | KMT2AMEN1THRATHRBCHRM2 | |
| SCHEMBL11037303 | 0.76 | KMT2A (0.39) | KMT2AMEN1THRATHRBCHRM2 | |
| SCHEMBL20409249 | 0.76 | FAAH (0.39) | KMT2AMEN1THRATHRBKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009148659-A2 | ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | NQO2, QTRT1, QTRT2 | KMT2A 1241/4885MEN1 2988/4885MAPT 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.